This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gómez-Pérez, F. J Articles by Parsons, B. Search for Related Content Social Bookmarking                         What's this?

Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, fgomezp{at}prodigy.net.mx

Armando Perez-Monteverde

Centro Medico Docente La Trinidad, Caracas, Venezuela

Osvaldo Nascimento

Fluminense Federal University, Rio de Janeiro, Brazil

Pablo Aschner

Colombian Diabetes Association, Bogotá, Colombia

Marino Tagle

Teodoro Maldonado Hospital, Guayaquil, Ecuador

Klaus Fichtner

Latin American CRO Mmatiss, Mexico City, Mexico

Ponni Subbiah

Pfizer Inc., New York, NY, USA

Elizabeth M Mutisya

Pfizer Inc., New York, NY, USA

For The Latin American Diabetic Neuropathy Study Group

Bruce Parsons

Pfizer Inc., New York, NY, USA

Objective

To determine whether gabapentin titrated to achieve clinical effect ( 50% reduction in pain; 900—3,600 mg/day) provides superior efficacy to a commonly prescribed fixed-dose (900 mg/day) in subjects with PDN.

Methods

In Latin America, an open-label trial randomised 339 subjects with PDN to gabapentin, 900 mg/day, for seven weeks (n=170), or to 900—3,600 mg/day titrated over four weeks to achieve clinical effect, followed by three weeks at stable dose (n=169).

Results

Gabapentin produced a significantly greater reduction in final weekly mean pain scores from baseline when titrated to clinical effect than when administered as a fixed-dose regimen (53.6% vs. 43.3%; p=0.009). Responder rate was significantly increased (64.5% vs. 47.5%; p=0.002), mean VAS scores significantly decreased, final weekly sleep interference scores significantly decreased (57% C vs. 37.2%; p=0.013), and trends favouring improvement in global functioning and QOL were seen in the titration to clinical effect group (p<0.001). Both regimens were well-tolerated.

Conclusions

Titration to clinical effect offered superior efficacy in treating PDN compared to a low fixed-dose treatment. Br J Diabetes Vasc Dis 2004;4:173—8

Key Words: neuropathic pain • gabapentin • dose titration.

References

• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1-S85.[Medline] [Order article via Infotrieve]
• Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.[Abstract]
• Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the U.S.:1990-1998. Diabetes Care 2000;23:1278-83.[Abstract/Free Full Text]
• Mokdad AH, Ford ES, Bowman BA et al. The continuing increase of diabetes in the U.S. Diabetes Care 2001;24:412.[Free Full Text]
• Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.[Abstract]
• Albala C., Vio F., Kain J., Uauy R. Nutrition transition in Latin America: the case of Chile. Nutr Rev 2001;59:170-6.[Web of Science][Medline] [Order article via Infotrieve]
• Uauy R., Albala C., Kain J. Obesity trends in Latin American transiting from under- to overweight. J Nutr 2001;131:893S-899S.[Abstract/Free Full Text]
• Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev 2002;18(suppl 3):S27-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1-85.[Medline] [Order article via Infotrieve]
• Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab 1977;3:245-56.[Web of Science][Medline] [Order article via Infotrieve]
• Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.[Abstract/Free Full Text]
• Jensen PG, Larson JR Management of painful diabetic neuropathy. Drugs Aging 2001;18:737-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tremont-Lukats IW, Megeff C., Backonja MM Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000;60:1029-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rull JA, Quibrera R., Gonzalez-Millan H., Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol):double blind crossover trial. Diabetologia 1969;5: 215-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gomez-Perez FJ, Choza R., Rios JM et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996;27:525-9.[Web of Science][Medline] [Order article via Infotrieve]
• Backonja M., Beydoun A., Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.[Abstract/Free Full Text]
• Rowbotham M., Harden N., Stacey B., Bernstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.[Abstract/Free Full Text]
• Eisenberg E., Lurie Y., Braker C., Daoud D., Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-09.[Abstract/Free Full Text]
• Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Serpell MG Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000;101:359-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.[Web of Science][Medline] [Order article via Infotrieve]
• Goldlust A., Su TZ, Welty DF, Taylor CP, Oxender DL Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 1995;22(1):1-11.[Medline] [Order article via Infotrieve]
• Gee NS, Brown JP, Dissanayake VU, Offord J., Thurlow R., Woodruff GN The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76.[Abstract/Free Full Text]
• Stefani A., Spadoni F., Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37(1):83-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Block F. [Gabapentin therapy for pain]. Nervenarzt 2001;72(2):69-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gotz E., Feuerstein TJ, Lais A., Meyer DK Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43:636-8.[Medline] [Order article via Infotrieve]
• Petroff OA, Rothman DL, Behar KL, Lamoureux D., Mattson RH The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39(1):95-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Beydoun A., Uthman BM, Sackellares JC Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995;18:469-81.[Web of Science][Medline] [Order article via Infotrieve]
• Boyd RA, Turck D., Abel RB, Sedman AJ, Bockbrader HN Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 1999;40:474-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.[Abstract/Free Full Text]
• Anhut H., Ashman P., Feuerstein TJ, Sauermann W., Saunders M., Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Laird MA, Gidal BE Use of gabapentin in the treatment of neuropathic pain. Ann Pharmacother 2000;34:802-07.[Abstract]
• NFO Worldgroup Report to Pfizer, 2002.
• Ware JE Jr, Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83.[Web of Science][Medline] [Order article via Infotrieve]
• Rosenberg JM, Harrell C., Ristic H., Werner RA, de Rosayro AM The effect of gabapentin on neuropathic pain. Clin J Pain 1997;13:251-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.[Abstract/Free Full Text]
• Perez HE, Sanchez GF Gabapentin therapy for diabetic neuropathic pain. Am J Med 2000;108:689.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gorson KC, Schott C., Herman R., Ropper AH, Rand WM Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2.[Free Full Text]
• Hemstreet B., Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther 2001;23:520-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McLean ML Gabapentin in the management of convulsive disorders. Epilepsia 40(suppl 6):S39-50; discussion S73-4. Review 1999.[CrossRef][Web of Science]
• Dougherty JA, Rhoney DH Gabapentin: a unique anti-epileptic agent. Neurol Res 2001;23:821-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Package insert for Neurontin. 2002.

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 3, 173-178 (2004)
DOI: 10.1177/14746514040040030601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gómez-Pérez, F. J Articles by Parsons, B. Search for Related Content Social Bookmarking                         What's this?